DOP024 Pregnancy outcomes after exposure to certolizumab pegol: Results from safety surveillance

U. Mahadevan1, S. Vermeire2 *, D.C. Wolf3, F. Forger4, J.J. Cush5, A. Golembesky6, L. Shaughnessy6, D. De Cuyper7, S. Abbas8, M.E.B. Clowse9. 1UCSF Medical Center, San Francisco, United States, 2University Hospital Gasthuisberg, Division of Gastroenterology, Leuven, Belgium, 3Atlanta Gastroenterology Associates, Atlanta, United States, 4University of Bern, Department of Rheumatology and Clinical Immunology and Allergology, Bern, Switzerland, 5Baylor Research Institute and Baylor University Medical Center, Dallas, United States, 6UCB Pharma, Raleigh, United States, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Paris, France, 9Duke University Medical Center, Rheumatology, Durham, United States